Study protocol: Comparison of different risk prediction modelling approaches for COVID-19 related death using the OpenSAFELY platform.

Publication date: Dec 12, 2024

On March 11th 2020, the World Health Organization characterised COVID-19 as a pandemic. Responses to containing the spread of the virus have relied heavily on policies involving restricting contact between people. Evolving policies regarding shielding and individual choices about restricting social contact will rely heavily on perceived risk of poor outcomes from COVID-19. In order to make informed decisions, both individual and collective, good predictive models are required. For outcomes related to an infectious disease, the performance of any risk prediction model will depend heavily on the underlying prevalence of infection in the population of interest. Incorporating measures of how this changes over time may result in important improvements in prediction model performance. This protocol reports details of a planned study to explore the extent to which incorporating time-varying measures of infection burden over time improves the quality of risk prediction models for COVID-19 death in a large population of adult patients in England. To achieve this aim, we will compare the performance of different modelling approaches to risk prediction, including static cohort approaches typically used in chronic disease settings and landmarking approaches incorporating time-varying measures of infection prevalence and policy change, using COVID-19 related deaths data linked to longitudinal primary care electronic health records data within the OpenSAFELY secure analytics platform.

Open Access PDF

Concepts Keywords
Death COVID-19
March infectious disease
Virus mortality
Wellcome risk prediction
statistical methodology

Semantics

Type Source Name
disease MESH COVID-19
disease MESH death
disease MESH infectious disease
pathway REACTOME Infectious disease
disease MESH infection
disease IDO quality
disease MESH chronic disease
disease IDO infection prevalence
drug DRUGBANK Ademetionine
drug DRUGBANK Aspartame
pathway REACTOME Reproduction
disease MESH general health
drug DRUGBANK Coenzyme M
disease MESH complications
drug DRUGBANK L-Aspartic Acid
drug DRUGBANK Trestolone

Original Article

(Visited 2 times, 1 visits today)